We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Elevated Circulating Fatty Acid Synthase Is a Diagnostic Biomarker for Peripheral Artery Disease

By LabMedica International staff writers
Posted on 11 Oct 2021
Print article
Image: Pictured is a cross section of a peripheral artery from the leg of a patient with chronic limb-threatening ischemia (CLTI), a condition in which heavy plaque formation causes a severe narrowing of the arteries (Photo courtesy of Zayed Research Laboratory, Washington University School of Medicine)
Image: Pictured is a cross section of a peripheral artery from the leg of a patient with chronic limb-threatening ischemia (CLTI), a condition in which heavy plaque formation causes a severe narrowing of the arteries (Photo courtesy of Zayed Research Laboratory, Washington University School of Medicine)
Elevated levels of a soluble form of the enzyme fatty acid synthase (sFSA) in the blood have been linked to development of the severe vascular disorder peripheral artery disease (PAD).

Fatty acid synthase is a multi-enzyme protein that catalyzes fatty acid synthesis. It is not a single enzyme but a whole enzymatic system composed of two identical multifunctional polypeptides, in which substrates are handed from one functional domain to the next. The main function of FSA is to catalyze the synthesis of palmitate (C16:0, a long-chain saturated fatty acid) from acetyl-CoA and malonyl-CoA, in the presence of NADPH.

In 2015, about 155 million people had PAD worldwide, and it becomes more common with age. In the developed world, PAD affects about 5.3% of 45- to 50-year-olds and 18.6% of 85- to 90-year-olds. In the United States PAD impacts some 12 million people. Among them at least 10% will progress to develop chronic limb-threatening ischemia (CLTI), a condition characterized by severe lower extremity arterial insufficiency, rest pain, non-healing wounds/ulcers, and gangrene.

There are currently no serum-based evaluations that can corroborate the severity of PAD. Therefore, in order to improve prognosis, the Global Vascular Guidelines recently highlighted the need for early diagnosis and aggressive medical management of patients. In this regard, investigators at Washington University School of Medicine (St. Louis, MO, USA) assessed the prevalence of elevated serum fatty acid synthase (cFAS) in patients with CLTI and evaluated the accuracy of its use in detecting this condition. This approach was based on prior studies showing that serum circulating FAS was elevated in patients with atherosclerotic carotid artery stenosis, and FAS content in carotid plaque was higher in maximally diseased segments.

For the current study, the investigators obtained and analyzed blood samples from 87 patients before they underwent vascular surgery to treat CLTI. Results revealed that elevated cFAS content, type II diabetes, and smoking were independently associated with CLTI and could detect the presence of CLTI with 83% accuracy. Levels cFAS in the blood were associated with the FAS content of plaque sampled from the femoral artery, the main vessel supplying blood to the legs. In addition, cFAS was found to circulate through the bloodstream while bound to the cholesterol transporter, low-density lipoprotein (LDL).

“These patients are at risk of losing their legs, which is devastating to quality of life,” said senior author Dr. Mohamed A. Zayed, associate professor of surgery and radiology at Washington University School of Medicine. “They lose their capacity to walk, and about half of them die within the next two years. We need to identify these patients sooner, so we can help treat them aggressively much earlier in the disease course. Our data suggest that levels of cFAS in the blood could be an accurate predictor for which patients are at high risk of the severe forms of this condition.”

“Oftentimes, I will see patients in my practice who have high LDL but are otherwise healthy individuals - they do not have evidence of disease in their arteries,” said Dr. Zayed. “Our guidelines tell us to be aggressive in treating these patients. But my suspicion is the problem is not just LDL. Rather, the problem is enzymes that are attached to LDL that are conferring the cardiovascular disease that we see, particularly in the peripheral arteries, as well as the coronary arteries that deliver blood to the heart and the carotid arteries that deliver blood to the brain.”

The study was published in the September 29, 2021, online edition of the journal Scientific Reports.

Related Links:
Washington University School of Medicine

Gold Supplier
Lactate Dehydrogenase (LDH) Assay
Assayed Hemoglobin Control
Cytology Sample Processor
SDSCP9000 CytoPath Processor
SARS-CoV-2 Antigen Immunofluorescence System
Watmind SARS-CoV-2 Antigen Immunofluorescence System

Print article



view channel
Image: The Gazelle Hb Variant Test for screening, diagnosis and management of sickle cell disease and related hemoglobinopathies at the point of care (Photo courtesy of Hemex Health)

Point-of-Care Device Accurately Rapidly Diagnoses Sickle Cell Disease

Hemoglobinopathies are the most common autosomal hereditary disorders. Approximately 7% of the global population carries hemoglobin gene mutation including structural hemoglobin variants like sickle hemoglobin... Read more


view channel
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)

Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results... Read more


view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more


view channel

AI Accurately Detects and Diagnoses Colorectal Cancer from Tissue Scans As Well or Better Than Pathologists

Artificial intelligence (A) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study. The study, which was conducted by researchers... Read more


view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more


view channel

Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases

The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.